S
Shiva S. Forootan
Researcher at University of Liverpool
Publications - 26
Citations - 920
Shiva S. Forootan is an academic researcher from University of Liverpool. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 15, co-authored 25 publications receiving 788 citations.
Papers
More filters
Journal ArticleDOI
Prognostic significance of osteopontin expression in human prostate cancer
Shiva S. Forootan,Christopher S. Foster,Vijay R. Aachi,Janet Adamson,Paul H. Smith,Ke Lin,Youqiang Ke +6 more
TL;DR: The hypothesis that expression of osteopontin (OPN), an integrin‐binding glycoprotein, can independently predict the potential aggressiveness of prostate cancer is supported and the increased OPN level may be involved in the malignant transformation of prostate epithelial cells and OPN expression level is an important determinant for patient survival is suggested.
Journal ArticleDOI
Ribosomal protein L19 is a prognostic marker for human prostate cancer
Alix Bee,Youqianq Ke,Shiva S. Forootan,Ke Lin,Carol Beesley,Sharon E. Forrest,Christopher S. Foster +6 more
TL;DR: Investigation of gene expression profiles between benign and malignant human prostate cell lines identified the gene encoding ribosomal protein L19 (RPL19) to be overexpressed in the malignant cells, revealing RPL19 to be a sensitive predictor of prostate cancer progression.
Journal ArticleDOI
Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients
Yu Zhang,Shiva S. Forootan,D Liu,Roger Barraclough,Christopher S. Foster,Philip S. Rudland,Youqiang Ke +6 more
TL;DR: The results suggest that increased AGR2 expression is a valuable prognostic factor to predict the clinical outcome of the prostate cancer patients.
Journal ArticleDOI
Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression.
Elwin A Morgan,Shiva S. Forootan,Janet Adamson,Christopher S. Foster,Hiroshi Fujii,Michihiro Igarashi,Carol Beesley,Paul H. Smith,Youqiang Ke +8 more
TL;DR: The results suggest that C-FABP may be used as a potential prognostic marker to predict patient outcome and the increased C-fABP expression is a possible target to inhibit the malignant progression of prostate cancer cells.
Journal ArticleDOI
Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.
Farzad Seyed Forootan,Shiva S. Forootan,Xiaojun Gou,Jin Yang,Bichong Liu,Danqing Chen,Majed Saad Al Fayi,Waseem Al-Jameel,Philip S. Rudland,Syed A. Hussain,Youqiang Ke +10 more
TL;DR: The results suggested that the FABP5-PPARγ-VEGF signal transduction axis, rather than androgen modulated route, may be a more important novel therapeutic target for angiogenesis-suppression treatment of castration resistant prostate cancer.